Autobahn Therapeutics to Join Several Upcoming Investor Conferences

Autobahn Therapeutics, a biotechnology firm based in San Diego, is focused on developing innovative treatments for individuals suffering from neuropsychiatric and neuroimmunologic disorders. The company utilizes a specialized brain-targeting chemistry platform to advance its portfolio of clinical candidates aimed at treating these conditions.

Kevin Finney, who serves as the President and Chief Executive Officer of Autobahn Therapeutics, will be representing the company at two major investor conferences in September. The first of these is the 2024 Cantor Global Healthcare Conference, scheduled for September 17, 2024, in New York, NY. The second event is the 2024 BofA Healthcare Trailblazers Private Company Conference, which will take place on September 25, 2024, in Boston, MA.

At these conferences, Kevin Finney will engage in investor meetings, providing updates on the company's progress and future plans. These meetings represent key opportunities for Autobahn Therapeutics to attract potential investors and strengthen its financial support for ongoing and future projects.

Autobahn Therapeutics' approach to drug development is characterized by its focus on precision tuning of central nervous system (CNS) exposure and the pursuit of validated clinical and biological targets. The company employs biomarkers to guide the development of its therapeutic candidates, ensuring a more targeted and effective treatment process.

The leading candidate in Autobahn Therapeutics' pipeline is ABX-002, a thyroid hormone receptor beta (TRβ) agonist. This compound is being developed as a potential adjunctive treatment for major depressive disorder and bipolar disorder depression. The innovative nature of ABX-002 lies in its ability to target specific receptors in the brain, potentially offering a new and more effective treatment option for patients suffering from these debilitating conditions.

Through its advanced scientific approach and strategic participation in key investor events, Autobahn Therapeutics aims to make significant strides in the field of neuropsychiatric and neuroimmunologic treatment. The company's commitment to leveraging cutting-edge technology and research underscores its mission to improve the lives of individuals affected by these disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!